REG - Kanabo Group PLC - AGM Statement

KanaboAnnouncement

30/06/2022 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220630:nRSd8871Qa&default-theme=true

RNS Number : 8871Q  Kanabo Group PLC  30 June 2022

 

Kanabo Group Plc.

("Kanabo" or the "CResult of Annual General Meeting

 

Kanabo Group Plc is pleased to announce that, at the Annual General Meeting
("AGM") held earlier today, all resolutions were duly passed. The numbers of
votes for each resolution are presented below:

 

                                                                                    Chairman of the meeting      Chairman of the meeting                         ABSTAIN

                                                                                    FOR                          AGAINST

                                                                                                                                              Total Votes Cast
 Resolution                                                                         No. of shares  %             No. of shares  %

 1       Receive Financial Statements                                               115,542,133    99.75451      284,339        0.245487      115,826,472        142,706
 2       Approve the Directors' Remuneration Report                                 115,458,280    99.69236      356,288        0.307637      115,814,568        154,610
 3       Approve the re-appointment of the auditors and authorize the directors to  115,553,226    99.75257      286,620        0.247428      115,839,846        129,332
         determine the Auditors' Remuneration
 4       Re-elect Andrew Morrison                                                   113,469,744    97.99032      2,327,150      2.009683      115,796,894        172,284
 5       Re-elect Avihu Israel Tamir                                                115,502,424    99.74567      294,510        0.254333      115,796,934        172,244
 6       Re-elect David Tsur                                                        115,508,799    99.75078      288,595        0.249224      115,797,394        171,784
 7       Elect Daniel Poulter                                                       115,509,839    99.75164      287,595        0.24836       115,797,434        171,744
 8       Elect Gil Efron                                                            115,509,839    99.75164      287,595        0.24836       115,797,434        171,744
 9       Authorise the directors to allot securities                                115,468,984    99.72081      323,278        0.279188      115,792,262        176,916
 10*     Authorise the directors to allot Equity Securities                         115,469,484    99.72081      323,278        0.279187      115,792,762        176,416

* Special Resolution

 

NOTES:

Votes "For" and "Against" are expressed as a percentage of votes received.

 

 

 

 

For further information, please visit http://www.kanabogroup.com/ or
https://www.voxmarkets.co.uk/listings/LON/KNB
(https://www.voxmarkets.co.uk/listings/LON/KNB) or contact the following:

 

 Kanabo Group Plc                            Via Vox Markets
 Avihu Tamir, CEO
 Peterhouse Capital Ltd (Financial Adviser)  Tel: +44 (0)20 7469 0930
 Eran Zucker / Lauren Riley

 Peterhouse Capital Ltd (Corporate Broker)

 Lucy Williams / Charles Goodfellow

 Duncan Vasey / Martin Lampshire

 Vox Markets (Investor Relations)            KanaboGroup@voxmarkets.co.uk
 Kat Perez                                   kperez@voxmarkets.co.uk

 

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry
to improve the well-being of millions of people around the world by providing
a better alternative to the smoking of medicinal cannabis flowers. Kanabo,
which was the first medicinal cannabis company to IPO on London Stock
Exchange, has a focus on the distribution of cannabis-derived products for
medical patients and non-THC products for CBD consumers.

 

The Company has conducted extensive Research & Development to produce
high-quality cannabis extract formulas, innovative medical-grade vaporizers,
and various non-smoking consumption solutions. Kanabo sells a range of medical
cannabis products and wellness CBD products in the Primary Markets, including
its VapePod, which delivers a metered dose with every inhalation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMEALKEDAKAEFA